OCARINA I: SC Ocrelizumab in MS

Phase 1, open-label trial of ocrelizumab in multiple sclerosis (MS) (4 arms), sponsored by Roche. Primary endpoints: Area Under the Serum Concentration-Time Curve (AUC) of Ocrelizumab following subcutaneous (SC) administration at 5 years, Area Under the Serum Concentration-Time Curve (AUC) of Ocrelizumab following single IV administration at 5 years and 4 more. Started Aug 2019; status: completed.